血小板自身抗体特异性与原发性免疫性血小板减少症患者对rhTPO治疗的反应
本回顾性研究纳入123例一线治疗失败后的成人ITP患者,检测血浆抗GPIIb/IIIa和抗GPIb/IX自身抗体,并分析其与rhTPO疗效的关系。提示抗GPIb/IX抗体可能是rhTPO治疗反应差的预测因素。
要点
- 抗GPIb/IX抗体或可作为预测rhTPO治疗反应差的指标。
核心结论
- 抗GPIb/IX自身抗体的存在可能与成人ITP患者对rhTPO治疗反应差相关。
研究设计与样本
- 回顾性研究,纳入123例一线治疗失败的成人ITP患者,检测血浆抗GPIIb/IIIa和抗GPIb/IX自身抗体并分析其与rhTPO疗效的关系。
临床怎么用
- 对一线治疗失败的成人ITP患者,检测抗GPIb/IX抗体可能有助于预判rhTPO治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This retrospective study aimed to evaluate the relationship between plasma autoantibody species and rhTPO response in adult ITP patients who failed the first-line treatments. Plasma anti-glycoprotein (GP) IIb/IIIa and anti-GPIb/IX autoantibodies were detected in 47·2% and 40·6% of the 123 patients, respectively. Overall response rate to rhTPO treatment in patients without anti-GPIb/IX autoantibodies was significantly higher than patients with anti-GPIb/IX autoantibodies (82·2% vs. 60·0%, P = 0·006). By contrast, no statistical difference in response rate was observed between patients with or without anti-GPIIb/IIIa autoantibodies (74·1% vs. 72·3%, P = 0·819). Therefore, the presence of anti-GPIb/IX autoantibodies might serve as a predictive factor for poor response to rhTPO treatment in ITP.
引用
- Yu Y, Hou Y, Zhao Y, et al. Platelet autoantibody specificity and response to rhTPO treatment in patients with primary immune thrombocytopenia. Br J Haematol. 2021. PMID: 33993469. doi:10.1111/bjh.17510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。